Tokyo, Japan – 26 January 2017: Sosei Group Corporation (“Sosei”; TSE Mothers Index:4565) is pleased to confirm that the combined annual sales of Seebri® Breezhaler® (glycopyrronium) and Ultibro® Breezhaler® (indacaterol/glycopyrronium), as reported in Novartis Q4, 2016 results announcement yesterday, were USD512 million.
Under the terms of the Novartis Licence Agreement, as the total annual sales of these COPD products have now exceeded USD500 million in a calendar year, Sosei is entitled to receive a one-off milestone payment of USD5 million.
Peter Bains, CEO of Sosei said; "We are delighted to see continued strong growth of Ultibro® Breezhaler® in response to the FLAME study results and the updated GOLD 2017 report which recommended the first-line use of dual bronchodilators, such as Ultibro® Breezhaler®, in the treatment of the majority of symptomatic chronic obstructive pulmonary disease (COPD) patients. Additionally, the combined 2016 sales of both COPD products have now exceeded the $500m milestone payment threshold. We look forward to the launch of Seebri™ Neohaler® and Utibron™ Neohaler® in the US to further drive sales momentum."
We do not disclose further details of agreement with Novartis.